Soft Tissue Sarcoma

New Indication: Atezolizumab for Advanced Alveolar Soft Part Sarcoma

Open-label, multicenter, phase 2 study

Unresectable or metasatic ASPS

Atezolizumab 1200 mg in adults (n=49) or 15 mg/kg (1200 mg max) in pediatric pts (n=3) once q21 days

ORR: 37% [19 of 52 pts]

mDoR: 24.7 mos [4.1-55.8]

mPFS: 20.8 mos

Any grade AEs: Musculoskeletal pain (67%); fatigue (55%); rash (47%); cough (45%); nausea, headache, and hypertension (43% each).

Reviewed by Elvin Chalabiyev, MD on Sep 23, 2023

atezolizumab